BioSpace News Archive

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced members of its management team will participate at the following investor conferences in September 2022.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that Stephen Hoge, M.D., President, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13th at 10:00 a.m. ET.

Sientra, Inc., a medical aesthetics company uniquely focused on plastic surgeons, announced that on August 29, 2022, the Company approved equity award grants under the Sientra Inc. Inducement Plan to 49 new employees.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in investor meetings at the Citi 17th Annual BioPharma Conference on September 7 – 8, 2022 in Boston, Massachusetts.

SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced that Howard Bernstein, M.D., Ph.D., has been appointed to the company’s board of directors, effective October 31, 2022.

The U.S. Food and Drug Administration is alerting patients, caregivers and health care providers that Philips Respironics has recalled certain masks used with bilevel positive airway pressure machines and continuous positive airway pressure machines due to a serious safety concern.

Sirnaomics Ltd. announced that Dr. Patrick Lu, PhD, founder, Chairman of the Board, Executive Director, President, and CEO of Sirnaomics, will present at the 3rd Annual Jefferies Asia Forum that will be held on September 8, 2022.

Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission (EC) has approved its CAR T-cell therapy Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and above with relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukemia (ALL).

Organism’s immune system creates a sub-type of protein called immune repertoire.

The global Life Science Analytics market size is expected to be worth around US$ 23.2 billion by 2030, according to a new report by Vision Research Reports.